Cochlear

Cochlear OpEx/Revenue

The Operating Expenses to Revenue Ratio of Cochlear (COH.AX) as of Oct 27, 2026 is 57.64 %. In the previous year, Operating Expenses to Revenue Ratio was 21.31 % — a change of 170.43% (higher).

OpEx/Revenue

57.64 %

YoY

170.43%

Last updated:

Operating Expenses to Revenue Ratio of Cochlear is 2026 57.64 % . Operating Expenses to Revenue Ratio of Cochlear was 2025 21.31 % . It decreases by 170.43% higher compared to the previous year.

The Cochlear OpEx/Revenue history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

OpEx/Revenue
Date
OpEx/Revenue
Jan 1, 2019
19.57 AUD
Jan 1, 2020
20.62 AUD
Jan 1, 2021
20.83 AUD
Jan 1, 2022
22.53 AUD
Jan 1, 2023
23.18 AUD
Jan 1, 2024
21.90 AUD
Jan 1, 2025
21.31 AUD
Jan 1, 2026
57.64 AUD
The Cochlear OpEx/Revenue history
YEAROpEx/RevenueYoY
57.64 %+170.43%
21.31 %-2.68%
21.90 %-5.52%
23.18 %+2.90%
22.53 %+8.13%
20.83 %+1.01%
20.62 %+5.39%
19.57 %+0.67%
19.44 %+2.80%
18.91 %-3.88%
19.67 %+0.14%
19.65 %-7.91%
21.33 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cochlear Stock analysis

What does Cochlear do? Cochlear Ltd is an Australian-based medical technology company founded in 1981 by engineer Professor Graeme Clark. The company specializes in Cochlear implant systems and other hearing devices. Cochlear Ltd offers accessories, services, and rehabilitation training for individuals with hearing impairments. The company's products are available for both children and adults with varying degrees of hearing loss. Cochlear Ltd operates in different sectors, including Cochlear implant systems, hearing aids, and wireless accessories and streaming systems under the brand names Nucleus® and Baha®. Nucleus® systems utilize a fully implantable cochlear implant and external speech processor to convert sound into electrical signals for interpretation by the brain. Baha® systems are bone-anchored hearing devices for individuals with unilateral to moderate hearing impairments. Cochlear Ltd also provides wireless accessories and streaming systems to connect devices like mobile phones, TVs, and music players to the hearing aids and cochlear implants, improving hearing performance and enhancing social lives. The company has a strong global presence, operating in over 100 countries with headquarters in Australia, multiple production facilities, and research centers. Cochlear Ltd has received numerous awards and recognition for its products and services and is committed to researching and developing new therapies and technologies to improve the lives of individuals with hearing impairments. Cochlear is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Cochlear stock

Operating Expenses to Revenue Ratio of Cochlear is 57.64 % in 2026.

Operating Expenses to Revenue Ratio of Cochlear changed from 21.31 % to 57.64 %, representing a 170.43% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Operating Expenses to Revenue Ratio Cochlear since 2006 – with annual values, charts, and detailed analysis.

The OpEx/Revenue ratio measures total operating expenses as a percentage of revenue. Declining ratios suggest improving operational leverage.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Operating Expenses to Revenue Ratio's Cochlear with sector peers and the industry average to assess whether it is attractive.

To evaluate Operating Expenses to Revenue Ratio's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Operating Expenses to Revenue Ratio.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — Cochlear

All Key Metrics — Cochlear